15 Essential Pharmaceuticals Stories for Healthcare Leaders

From investment-grade ratings on Sun Pharma's landmark Organon acquisition to a government expert panel examining unethical pharma marketing, this press review captures 15 defining developments across Indian print media. According to Press Monitor's tracking of Indian publications, these stories reflect the sector's momentum and regulatory evolution. This media monitoring roundup covers news on pharmaceuticals and life sciences, offering media intelligence on the deals, trials, and policy shifts shaping the industry.

1. Sun Pharma Gains Rating on 11.75 Billion Bid

A front-page report in Millennium Post says Moody’s Ratings and S&P Global Ratings have assigned investment-grade credit ratings to Sun Pharmaceutical Industries following its proposed 11.75 billion dollar acquisition of US-based Organon & Co. The company plans to secure a hundred percent stake in Organon through an enterprise value of 11.75 billion dollars, with transactions expected to close by March 2027 pending necessary approvals. Moody’s highlighted that Sun has arranged a 12 billion dollar bridge loan for the purchase, supported by cash holdings of roughly 3.6 billion dollars as of March 2026.

Why it matters: Investment-grade ratings from Moody's and S&P Global validate Sun Pharmaceutical Industries' financial strength ahead of its largest-ever acquisition, signaling confidence in the deal's execution.

Key detail/stat: The company plans to secure a hundred percent stake in Organon through an enterprise value of 11.75 billion dollars, with transactions expected to close by March 2027 pending necessary approvals. Sun has arranged a 12 billion dollar bridge loan supported by cash holdings of roughly 3.6 billion dollars as of March 2026.

Source: Millennium Post, New Delhi

Next step: Contact @SunPharma to share your perspective on this landmark deal.

2. Centre May Allow Doorstep Medicine Delivery

A front-page report in Mint says the central government is likely to permit doorstep medicine delivery across offline and online channels, overriding a proposal to rescind the pandemic-era policy. The Drugs Technical Advisory Board reviewed the matter on the twenty seventh of August, concluding that revoking the notification would severely impact elderly individuals, chronic disease sufferers, and rural residents. Although the All India Organisation of Chemists and Druggists flagged compliance issues regarding applications like Swiggy, regulators prioritized patient accessibility over stricter prescription enforcement.

Why it matters: The government's likely decision to retain doorstep medicine delivery could reshape pharmaceutical access for millions of elderly and rural patients across India.

Key detail/stat: The Drugs Technical Advisory Board reviewed the matter on 27 August, concluding that revoking the pandemic-era notification would severely impact elderly individuals, chronic disease sufferers, and rural residents.

Source: Mint, New Delhi, 27 August

Next step: Share this with @DTAB_India to amplify patient accessibility voices.

3. HDFC Pharma Fund Delivers 30% CAGR

A front-page report in The Pioneer says HDFC Asset Management Company Limited's Pharma and Healthcare Fund delivered a CAGR of 30.19% since inception and a return of 19.01% over one year as of July 31, 2026. The fund, launched on October 4, 2023, is managed by Nikhil Mathur and invests predominantly in equity instruments of pharma and healthcare companies in India.

Why it matters: A 30.19 percent compounded annual growth rate since inception demonstrates the strong performance potential of pharma-focused mutual funds in the Indian market.

Key detail/stat: The fund delivered a return of 19.01 percent over one year as of July 31, 2026, and is managed by Nikhil Mathur, investing predominantly in equity instruments of pharma and healthcare companies.

Source: The Pioneer, Mumbai

Next step: Tag @HDFCAMC in your comments on pharma fund performance.

4. Sandoz Targets Biosimilars Growth

A front-page report in Economic Times says Swiss drugmaker Sandoz aims to more than double its annual net sales by 2035, with a majority coming from biosimilar medicines. The company plans to increase its biosimilars portfolio to 100 drugs by 2040 from 13 currently, targeting mid-to-high single-digit percentage growth in total annual net sales at constant currencies from 2025 to 2030. Separately, the Competition Commission of India closed a case against Google over real-money games citing exceptional developments, including the implementation of the Online Gaming Act.

Why it matters: Sandoz's ambition to more than double annual net sales by 2035 signals a major strategic bet on biosimilars, which could reshape global competition in affordable biologics.

Key detail/stat: The company plans to increase its biosimilars portfolio to 100 drugs by 2040 from 13 currently, targeting mid-to-high single-digit percentage growth in total annual net sales at constant currencies from 2025 to 2030.

Source: Economic Times, London

Next step: Comment below on whether biosimilars will disrupt the biologics market.

5. VIT Chennai and The Hindu Host Biotech Conclave 2026

A front-page report in The Hindu says The Hindu and the Vellore Institute of Technology, Chennai, will present the Biotech Conclave 2026 in Chennai on September 11. The day-long event will be inaugurated by CII president designate Suchitra Ella and presided over by VIT founder and chancellor G. Viswanathan, bringing together leading scientists, researchers, and healthcare leaders to explore emerging biotechnologies, research pathways, and career opportunities for students and aspirants.

Why it matters: Bringing together leading scientists, researchers, and healthcare leaders, this conclave highlights India's growing role in biotechnology and life sciences innovation.

Key detail/stat: The day-long event on September 11 will be inaugurated by CII president designate Suchitra Ella and presided over by VIT founder and chancellor G. Viswanathan.

Source: The Hindu, Chennai

Next step: Register your interest at @VIT Chennai and join the biotech conversation.

6. Punjab Drug Crisis After Villager's Death

A front-page report in Free Press Journal says rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries over the proposed 11.75-billion-dollar acquisition of US-based Organon and Co. S&P Global Ratings assigned a preliminary BBB+ long-term issuer credit rating, while Moody's Ratings assigned a Baa1 long-term issuer rating to the Indian pharmaceutical major. Both agencies have maintained a stable outlook for the company.

Why it matters: The alleged suicide of a villager who questioned drug supply raises urgent questions about governance and accountability in Punjab's pharmaceutical supply chain.

Key detail/stat: Gulzar Singh, a forty-seven-year-old villager from Dirba in Sangrur district, died after allegedly consuming poison following his questioning of Finance Minister Harpal Cheema about the unabated supply of chitta. Five people were booked under Section 108 of the BNS.

Source: Free Press Journal, Chandigarh/New Delhi

Next step: Tag @PunjabPolice and @HarpalCheema in the conversation on drug supply accountability.

7. Pharma Funds Rally 16.6 Per Cent

A front-page report in Business Standard says pharma and healthcare mutual funds have surged by sixteen point six percent over the past year, driven by structural growth opportunities in domestic and global markets. Fund experts advise investors to align fund selection with their risk appetite, considering factors such as portfolio breadth, market capitalisation orientation, and management style rather than chasing recent returns. Aggressive investors with a five to seven year horizon are best suited, with recommended exposure capped at five to ten percent of an equity portfolio.

Why it matters: A 16.6 percent surge in pharma and healthcare mutual funds over the past year reflects strong structural growth opportunities in the healthcare sector.

Key detail/stat: Fund experts advise investors to align fund selection with their risk appetite, considering factors such as portfolio breadth, market capitalisation orientation, and management style. Aggressive investors with a five to seven year horizon are best suited.

Source: Business Standard, Mumbai

Next step: Tag your financial advisor and share which pharma fund you are tracking.

8. Novartis Shares Drop Nine Percent

A front-page report in Business Standard says that on 18 July 2026, Novartis's experimental drug del-desiran failed a late-stage study for myotonic dystrophy, a muscle-wasting disease with no approved treatments. The setback, the second major trial failure in days, caused the Swiss drugmaker's shares to drop about nine percent in one of its worst trading days on record. Del-desiran was acquired through Novartis's $12 billion acquisition of Avidity.

Why it matters: A major clinical trial failure for del-desiran, acquired through a 12 billion dollar deal, underscores the high-risk nature of drug development and its impact on shareholder value.

Key detail/stat: On 18 July 2026, Novartis's experimental drug del-desiran failed a late-stage study for myotonic dystrophy, causing the Swiss drugmaker's shares to drop about nine percent in one of its worst trading days on record.

Source: Business Standard, New Delhi

Next step: @Novartis, how will you address investor concerns following this setback?

9. Expert Panel To Curb Pharma Marketing

A front-page report in Hindustan Times says the government has decided to constitute a three-member expert committee to examine whether pharmaceutical companies should be brought under a legally enforceable framework to prevent unethical marketing practices. The move follows a petition by the Federation of Medical and Sales Representatives' Associations of India and was disclosed in an affidavit filed before the Supreme Court.

Why it matters: A government expert committee examining unethical marketing practices could introduce new regulatory frameworks that reshape how pharmaceutical companies operate in India.

Key detail/stat: The three-member expert committee was constituted following a petition by the Federation of Medical and Sales Representatives' Associations of India, disclosed in an affidavit filed before the Supreme Court.

Source: Hindustan Times, New Delhi, 18 July 2026

Next step: @FICCI @CII, what is your take on enforceable marketing frameworks for pharma?

10. VERVE-102 Cuts LDL Cholesterol by 62%

A front-page report in Times of India says a single-dose intravenous gene editing therapy called VERVE-102, designed by US pharma company Eli Lilly, lowered LDL cholesterol by up to 62% in a phase 1 trial published in the New England Journal of Medicine. The US FDA has given fast track designation to VERVE-102 for treating those genetically prone to very high cholesterol or premature heart disease, with phase 2 planned by year-end.

Indian cardiologists caution about long-term safety given VERVE-101's earlier trial pause due to liver enzyme rise and low platelet count, though VERVE-102 uses improved liver targeting delivery.

Why it matters: A single-dose gene editing therapy achieving a 62 percent reduction in LDL cholesterol represents a potential paradigm shift in cardiovascular treatment.

Key detail/stat: The phase 1 trial, published in the New England Journal of Medicine, showed VERVE-102 designed by Eli Lilly lowered LDL cholesterol by up to 62 percent. The US FDA has given fast track designation with phase 2 planned by year-end.

Source: Times of India, New Delhi

Next step: @EliLilly, a breakthrough worth watching — share your thoughts on gene editing for heart health.

11. VERVE-lO2 Gene Editing for Cholesterol

A front-page report in Times of India says US biotech firm Verve Therapeutics' single-dose IV therapy VERVE-lO2 permanently switches off the PCSK9 gene in liver cells using lipid nanoparticle technology to reduce LDL cholesterol. Dr Kaul and Dr Singhvi caution that gene editing therapies would remain niche compared to statins, while Dr Mukherjee stresses lifestyle changes remain essential.

Why it matters: Verve Therapeutics' approach to permanently switching off the PCSK9 gene using lipid nanoparticle technology offers a complementary strategy to traditional statin therapy.

Key detail/stat: Dr Kaul and Dr Singhvi caution that gene editing therapies would remain niche compared to statins, while Dr Mukherjee stresses lifestyle changes remain essential for cholesterol management.

Source: Times of India

Next step: What is your view on gene editing as a cholesterol treatment? Share below.

12. Jagsonpal to Stop Rowezy-250 Marketing

A front-page report in The Pioneer says Jagsonpal Pharmaceuticals Limited intends to discontinue the marketing of its Rowezy-250 (1x10) tablet in India after a six-month period from the date of the notice. Patients using this Azithromycin dihydrate medicine are advised to consult their doctor for alternative prescriptions, and medical professionals are notified of the discontinuation.

Why it matters: A pharmaceutical company discontinuing a medicine highlights the importance of pharmacovigilance and patient safety in the Indian drug market.

Key detail/stat: Jagsonpal Pharmaceuticals Limited intends to discontinue the marketing of its Rowezy-250 tablet in India after a six-month period from the date of the notice. Patients are advised to consult their doctor for alternative prescriptions.

Source: The Pioneer, New Delhi

Next step: @Jagsonpal, how are you supporting patients through this transition?

13. Insilico Medicine AI Drug Slows Aging

A front-page report in Economic Times says Insilico Medicine's drug rentosertib helped reduce biological age as measured by six different ageing clocks in a mid-stage study. The analysis published in Nature Biotechnology included 42 patients with a chronic lung disease, and those who were given a placebo saw little change in their biological age on those same clocks.

Why it matters: Artificial intelligence-driven drug discovery is producing results in aging research, potentially opening new therapeutic avenues for age-related diseases.

Key detail/stat: Insilico Medicine's drug rentosertib helped reduce biological age as measured by six different ageing clocks in a mid-stage study of 42 patients with chronic lung disease, published in Nature Biotechnology.

Source: Economic Times

Next step: @InsilicoMedicine, this could reshape longevity research — what are your expectations?

14. Bihar Health Dept Seeks Transport Agency

A front-page report in Times of India says the State Health Society, Bihar has invited e-tenders for hiring transport services to deliver drugs, consumables, family planning commodities and other supplies till the lowest level health facilities across all districts of the state. Three levels of transportation services are planned from September 2026 for a three-year contract period, eligible bidders must register on the Bihar Government Centralized e-Procurement portal, with a pre-bid meeting scheduled at Swasthya Bhawan, Patna.

Why it matters: Strengthening the last-mile drug supply chain in Bihar could significantly improve healthcare access for underserved populations across the state.

Key detail/stat: The State Health Society, Bihar has invited e-tenders for hiring transport services for a three-year contract period, with three levels of transportation planned from September 2026.

Source: Times of India, Patna, 9 September 2026

Next step: @BiharHealth, improving last-mile delivery is a step in the right direction.

15. ChrysCapital to Buy 20-25% in Linux Labs

A front-page report in Economic Times says homegrown private equity firm ChrysCapital is set to acquire a 20-25% stake in Chennai-based CNS-focused domestic formulations company Linux Laboratories for around 60-65 million dollars (600 crore rupees). Tata Capital Healthcare Fund will exit its entire 15% stake as part of the transaction, while ChrysCapital will acquire an additional 5-10% stake through a primary capital infusion.

Why it matters: A homegrown private equity firm acquiring a significant stake in a Chennai-based CNS formulations company signals growing investor confidence in India's domestic pharmaceutical manufacturing.

Key detail/stat: ChrysCapital is set to acquire a 20-25 percent stake for around 60-65 million dollars, with Tata Capital Healthcare Fund exiting its entire 15 percent stake as part of the transaction.

Source: Economic Times, Mumbai, 18 July 2026

Next step: @ChrysCapital @TataCapital, a significant bet on India's CNS formulations space — what is your outlook?

This print media monitoring review highlights the breadth of developments shaping pharmaceuticals and life sciences in India. From deal-making to regulation, from clinical breakthroughs to policy shifts, these stories offer a comprehensive view of the sector's trajectory. Which trend are you tracking most closely this week?